Subsequent search iterations selected well-known regulators of EGFR activity in lung cancers, including mutations in epithelial-to-mesenchymal transition mediators SMAD4 and LAMC2, as well as ERBB2 (Liu et al., 2015; Moon et al., 2015), with the meta-feature being statistically significant based on the permuted null background obtained for the same search criterion (P ≤ 0.02; Supplementary Figure S4). Here, SMAD4 is linked to lung carcinoma.